396 related articles for article (PubMed ID: 31985078)
1. Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.
Stauder R; Lambert J; Desruol-Allardin S; Savre I; Gaugler L; Stojkov I; Siebert U; Chevrou-Séverac H
Eur J Haematol; 2020 May; 104(5):476-487. PubMed ID: 31985078
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia.
Bryant AL; Drier SW; Lee S; Bennett AV
Leuk Res; 2018 Jul; 70():106-116. PubMed ID: 29925044
[TBL] [Abstract][Full Text] [Related]
3. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
4. Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers.
Salas M; Henderson M; Wientzek-Fleischmann A; Islam Z; Tu N; Bilitou A; Elsharkawy M; Stellmacher U
Front Pharmacol; 2020; 11():1109. PubMed ID: 32792948
[TBL] [Abstract][Full Text] [Related]
5. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of patient-reported outcome measures for advanced skin cancer patients.
Reinhardt ME; Sun T; Pan CX; Schmults CD; Lee EH; Waldman AB
Arch Dermatol Res; 2023 Aug; 315(6):1473-1480. PubMed ID: 36469125
[TBL] [Abstract][Full Text] [Related]
7. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
Wang R; Zeidan AM; Yu JB; Soulos PR; Davidoff AJ; Gore SD; Huntington SF; Gross CP; Ma X
Prostate; 2017 Apr; 77(5):437-445. PubMed ID: 27868212
[TBL] [Abstract][Full Text] [Related]
9. Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis.
Booth A; Bell T; Halhol S; Pan S; Welch V; Merinopoulou E; Lambrelli D; Cox A
J Med Internet Res; 2019 Nov; 21(11):e14285. PubMed ID: 31755871
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis.
Marsà A; Ascanio M; Diaz-García J; Darbà J
J Med Econ; 2020 Dec; 23(12):1477-1484. PubMed ID: 33084440
[TBL] [Abstract][Full Text] [Related]
11. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
[TBL] [Abstract][Full Text] [Related]
12. Familial myelodysplastic syndrome/acute myeloid leukemia.
Churpek JE
Best Pract Res Clin Haematol; 2017 Dec; 30(4):287-289. PubMed ID: 29156196
[TBL] [Abstract][Full Text] [Related]
13. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
14. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
Babushok DV; Bessler M; Olson TS
Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
[TBL] [Abstract][Full Text] [Related]
15. A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Bell JA; Galaznik A; Pompilus F; Strzok S; Bejar R; Scipione F; Fram RJ; Faller DV; Cano S; Marquis P
J Patient Rep Outcomes; 2019 Jun; 3(1):35. PubMed ID: 31218454
[TBL] [Abstract][Full Text] [Related]
16. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes in acute myeloid leukemia: Where are we now?
Buckley SA; Kirtane K; Walter RB; Lee SJ; Lyman GH
Blood Rev; 2018 Jan; 32(1):81-87. PubMed ID: 28888621
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
19. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.
Oosterveld M; Suciu S; Muus P; Germing U; Delforge M; Belhabri A; Aul C; Selleslag D; Ferrant A; Marie JP; Amadori S; Jehn U; Mandelli F; Hess U; Hellström-Lindberg E; Cakmak-Wollgast S; Vignetti M; Labar B; Willemze R; de Witte T
Ann Hematol; 2015 Jan; 94(1):23-34. PubMed ID: 25096636
[TBL] [Abstract][Full Text] [Related]
20. Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.
Tomlinson B; de Lima M; Cogle CR; Thompson MA; Grinblatt DL; Pollyea DA; Komrokji RS; Roboz GJ; Savona MR; Sekeres MA; Abedi M; Garcia-Manero G; Kurtin SE; Maciejewski JP; Patel JL; Revicki DA; George TI; Flick ED; Kiselev P; Louis CU; DeGutis IS; Nifenecker M; Erba HP; Steensma DP; Scott BL
Transplant Cell Ther; 2023 Jul; 29(7):460.e1-460.e9. PubMed ID: 37086851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
